Castle Biosciences (CSTL) Competitors $20.35 +0.60 (+3.04%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$23.25 +2.90 (+14.25%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. ADUS, VCYT, PACS, WGS, LFST, ARDT, PGNY, NHC, GRAL, and TDOCShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Addus HomeCare (ADUS), Veracyte (VCYT), PACS Group (PACS), GeneDx (WGS), LifeStance Health Group (LFST), Ardent Health (ARDT), Progyny (PGNY), National HealthCare (NHC), GRAIL (GRAL), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors Addus HomeCare Veracyte PACS Group GeneDx LifeStance Health Group Ardent Health Progyny National HealthCare GRAIL Teladoc Health Addus HomeCare (NASDAQ:ADUS) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Do analysts recommend ADUS or CSTL? Addus HomeCare presently has a consensus price target of $142.57, suggesting a potential upside of 23.85%. Castle Biosciences has a consensus price target of $37.00, suggesting a potential upside of 81.82%. Given Castle Biosciences' higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Addus HomeCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, ADUS or CSTL? Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddus HomeCare$1.15B1.83$73.60M$4.4325.99Castle Biosciences$332.07M1.77$18.25M-$0.19-107.11 Does the media prefer ADUS or CSTL? In the previous week, Addus HomeCare had 8 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Addus HomeCare and 2 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.94 beat Addus HomeCare's score of 0.26 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADUS or CSTL more profitable? Addus HomeCare has a net margin of 6.52% compared to Castle Biosciences' net margin of -1.46%. Addus HomeCare's return on equity of 9.23% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Addus HomeCare6.52% 9.23% 6.96% Castle Biosciences -1.46%3.41%2.95% Which has more volatility and risk, ADUS or CSTL? Addus HomeCare has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Do institutionals & insiders hold more shares of ADUS or CSTL? 95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 4.6% of Addus HomeCare shares are held by insiders. Comparatively, 7.2% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryAddus HomeCare beats Castle Biosciences on 12 of the 17 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$587.50M$2.82B$5.45B$8.90BDividend YieldN/A2.70%5.35%4.14%P/E Ratio-107.1121.1626.2819.67Price / Sales1.77279.07410.60112.14Price / Cash20.6841.2925.7827.49Price / Book1.257.197.915.41Net Income$18.25M-$55.05M$3.16B$248.99M7 Day Performance7.96%1.53%2.62%2.85%1 Month Performance27.43%5.83%5.34%5.49%1 Year Performance-6.52%-0.74%32.02%16.97% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences2.6832 of 5 stars$20.35+3.0%$37.00+81.8%-6.5%$587.50M$332.07M-107.11540High Trading VolumeADUSAddus HomeCare4.7349 of 5 stars$113.01-0.7%$142.57+26.2%-0.9%$2.09B$1.15B25.5149,703Analyst UpgradeVCYTVeracyte3.4671 of 5 stars$26.71+1.2%$40.90+53.1%+26.3%$2.07B$445.76M65.15790Analyst DowngradePACSPACS Group2.7193 of 5 stars$12.77-3.1%$34.29+168.5%-55.9%$2.01B$3.11B0.0032,433WGSGeneDx1.8886 of 5 stars$79.71+19.0%$86.75+8.8%+248.5%$1.91B$305.45M73.631,200High Trading VolumeLFSTLifeStance Health Group2.4189 of 5 stars$4.96+2.7%$8.50+71.4%+4.9%$1.88B$1.25B0.0010,218ARDTArdent Health3.4089 of 5 stars$12.94-0.8%$20.67+59.7%N/A$1.87B$5.97B7.9524,900PGNYProgyny1.0699 of 5 stars$20.79-0.9%$23.45+12.8%-23.4%$1.80B$1.17B39.58310NHCNational HealthCareN/A$106.43+1.5%N/A-0.2%$1.65B$1.37B13.3412,400GRALGRAIL0.6686 of 5 stars$43.07-5.6%$31.50-26.9%N/A$1.64B$125.60M0.001,360Positive NewsTDOCTeladoc Health3.339 of 5 stars$7.90+14.5%$9.60+21.5%-13.8%$1.21B$2.57B-1.335,500Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Addus HomeCare Alternatives Veracyte Alternatives PACS Group Alternatives GeneDx Alternatives LifeStance Health Group Alternatives Ardent Health Alternatives Progyny Alternatives National HealthCare Alternatives GRAIL Alternatives Teladoc Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
